Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
|Podcasts|March 4, 2021
Podcast: Find out more about Allergan’s presbyopia drop NDA filing
Potential presbyopia treatment coming
Advertisement
Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.
Advertisement
Related to this article
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
2
More than monitoring: Using AMD visits to promote healthy vision aging
3
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
4
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
5